The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 29, 2017
Filed:
Dec. 20, 2013
Applicant:
Epizyme, Inc., Cambridge, MA (US);
Inventors:
Kenneth W. Duncan, Westwood, MA (US);
Richard Chesworth, Concord, MA (US);
Paula Ann Boriack-Sjodin, Lexington, MA (US);
Michael John Munchhof, Salem, CT (US);
Lei Jin, Wellesley, MA (US);
Assignee:
Epizyme, Inc., Cambridge, MA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 413/12 (2006.01); C07D 401/14 (2006.01); C07D 405/14 (2006.01); C07D 217/16 (2006.01); C07D 401/12 (2006.01); C07D 405/12 (2006.01); C07D 417/12 (2006.01); C07D 217/04 (2006.01); A61K 31/472 (2006.01); A61K 31/4725 (2006.01); A61K 31/497 (2006.01); A61K 31/498 (2006.01); A61K 31/502 (2006.01); A61K 31/517 (2006.01); A61K 31/5377 (2006.01); A61K 31/538 (2006.01); C07D 217/08 (2006.01);
U.S. Cl.
CPC ...
C07D 413/12 (2013.01); A61K 31/472 (2013.01); A61K 31/4725 (2013.01); A61K 31/497 (2013.01); A61K 31/498 (2013.01); A61K 31/502 (2013.01); A61K 31/517 (2013.01); A61K 31/538 (2013.01); A61K 31/5377 (2013.01); C07D 217/04 (2013.01); C07D 217/08 (2013.01); C07D 217/16 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 405/12 (2013.01); C07D 405/14 (2013.01); C07D 417/12 (2013.01);
Abstract
Described herein are compounds of Formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.